Author

Yunju Jo

Observed name: Jo, Yunju

Institutions: Korea University, Korea Institute of Science and Technology

Observed institutions: Korea University, Korean Association Of Science and Technology Studies, Korea Institute of Science and Technology

ORCID: 0000-0002-7038-7832

Observed ORCID: 0000-0002-7038-7832

OpenAlex ID: A5043034697

LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation

2022 · Eunsil Sung, Minkyung Ko, et al. · Molecular Therapy · 84

A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity

2023 · Dong-hee Lee, Hyejin Ahn, et al. · Journal of Experimental & Clinical Cancer Research · 23

Enhancing adoptive T‐cell therapy with fucoidan‐based IL ‐2 delivery microcapsules

2022 · Eun Young Jeon, Da‐som Choi, et al. · Bioengineering & Translational Medicine · 23

No more LAGging behind PD-1: uncovering the unique role of LAG-3 in T-cell exhaustion

2024 · Yunju Jo, Hyung-seung Jin, et al. · Cellular and Molecular Immunology · 6

Modulating CD226 and PD-(L)1 pathways improves CMV-specific CD8＋T cell responses in the absence of IL-2

2025 · Hye-In Sim, Yunju Jo, et al. · BMB Reports · 1

PD-L1-Directed CD226 Agonism Enhances Antitumor Activity by Amplifying T Cell Responses to Limiting Stimulation

2026 · Yunju Jo, Hyejin Ahn, et al. · Immune Network

Erratum to: Modulating CD226 and PD-(L)1 pathways improves CMV-specific CD8＋T cell responses in the absence of IL-2.

2025 · Hye-In Sim, Yunju Jo, et al. · PubMed Central

Works count: 9

Citation count: 137

H-index: 4

I10-index: 3